Navigation Links
Watson Confirms Amphastar Patent Lawsuit
Date:9/22/2011

PARSIPPANY, N.J., Sept. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Momenta Pharmaceuticals, Inc. and Sandoz Inc. have filed suit against Amphastar Pharmaceuticals, Inc. and Watson on September 21, 2011 in the United States District Court for the District of Massachusetts.  The suit alleges that Amphastar's Enoxaparin Sodium Injection product, which Watson has the exclusive right to distribute in the U.S. retail pharmacy channel, infringes Momenta's U.S. Patent Nos. 7,790,466 and 7,575,886.  Enoxaparin Sodium Injection is a generic equivalent to Sanofi-aventis' LOVENOX®.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Watson and Amphastar intend to vigorously defend the claims in the lawsuit.  Pursuant to terms of the distribution agreement between Watson and Amphastar, Watson believes it will be fully indemnified by Amphastar for all costs, expenses and damages, if any, incurred in connection with the lawsuit.About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Amphastar Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products. Amphastar's state-of-the-art, aseptic, cGMP compliant facilities develop, manufacture, and market innovative proprietary and generic products using new technologies and delivery systems.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LOVENOX® is a registered trademark of Sanofi-aventis U.S. LLC.CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 2016 RnRMarketResearch.com adds "Asthma - ... analysis of Asthma therapy at various stages, therapeutics assessment ... administration (RoA) and molecule type, along with latest updates, ... key players involved in the therapeutic development for Asthma ... Complete report on H1 2016 pipeline review of ...
(Date:5/30/2016)... 2016 According to a ... Market by Type (Stability, Raw Materials, Method Validation, ... (Pharmaceutical Companies, Medical Device Companies) - Global Forecast ... healthy growth during the last decade and is ... between 2016 and 2021 to reach USD 4.13 ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... The Global Wellness Summit (GWS), an annual conference for international ... travel, spa and beauty in Europe. The organization asked its partner experts in Europe ... researchers - to forecast where wellness is headed in Europe. Predictions range from European ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... The Orthopaedic ... executive committee members: , David G. Lewallen, MD, began his term as president ... president. Michael L. Parks, MD, is OREF’s new president-elect. Richard F. Kyle, MD, will ...
(Date:5/31/2016)... , ... May 31, 2016 , ... In a recent ... Feiner and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading medical ... what she calls the country’s “modern medical money maelstrom.” , During the interview ...
(Date:5/31/2016)... ... May 31, 2016 , ... To meet a growing demand ... industry, The University of Scranton is adding a Certificate in Health Informatics to ... in rapidly growing field of healthcare information. , Healthcare organizations are under ...
(Date:5/30/2016)... , ... May 30, 2016 , ... ... use inside of FCPX," said Christina Austin - CEO of Pixel Film Studios. ... use within Final Cut Pro X. Choose from abstract transitions to more simple ...
Breaking Medicine News(10 mins):